Spots Global Cancer Trial Database for Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
Official Title: A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors
Study ID: NCT04362748
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope National Medical Center, Duarte, California, United States
Indiana University, Indianapolis, Indiana, United States
Washington University, Saint Louis, Missouri, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
St Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia
Monash Medical Centre, Clayton, Victoria, Australia
Cliniques Universitaires Saint Luc, Bruxelles, , Belgium
Universitair Ziekenhuis Gent, Gent, , Belgium
Hospital Universitari Vall d Hebron, Barcelona, Cataluña, Spain
Hospital Clinic i Provincial de Barcelona, Barcelona, Cataluña, Spain
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
